SCHEMBL3860282

SCHEMBL3860282

CC(=O)Nc1cc2c3c(cc(NC(C)=O)cc3c1)C(=O)N(CCCP(=O)(O)O)C2=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.44
KLK7 P49862 1/20 0.42
FTO Q9C0B1 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
ALDH1A1 P00352 4/20 0.39
HPGD P15428 2/20 0.39
MAPT P10636 2/20 0.39
THRB P10828 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
HSD17B10 Q99714 1/20 0.36
ACHE P22303 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
KDM4E B2RXH2 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
GAA P10253 1/20 0.36
MEN1 O00255 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3852558 0.84 KMT2A (0.54) KMT2AKLK7FTOCYP1A2CYP3A4
SCHEMBL3853310 0.81 KMT2A (0.43) KMT2AKLK7FTOCYP1A2CYP3A4
SCHEMBL3852327 0.81 HPGD (0.54) KMT2AKLK7ALDH1A1HPGDMAPT
SCHEMBL3860317 0.79 ALDH1A1 (0.46) KMT2ACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4152854 0.78 KMT2A (0.48) KMT2AKLK7CYP1A2CYP3A4CYP2D6
SCHEMBL3850344 0.78 CYP2D6 (0.46) KMT2AFTOCYP1A2CYP2D6ALDH1A1
SCHEMBL14557208 0.77 KLK7 (0.57) KMT2AKLK7FTOCYP1A2CYP3A4
SCHEMBL3851575 0.75 KMT2A (0.67) KMT2AKLK7FTOCYP1A2CYP3A4
SCHEMBL7709776 0.75 KLK7 (0.53) KMT2AKLK7ALDH1A1HPGDMAPT
SCHEMBL3850799 0.73 FTO (0.56) KMT2AFTOMAPTTHRBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931637-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2008-06-18 EP claimed
US-20070093474-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-04-26 US claimed
WO-2007030940-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO claimed
US-7579468-B2 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2009-08-25 US disclosed
US-7579468-B2 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2009-08-25 US disclosed
US-7579468-B2 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2009-08-25 US disclosed
US-20070093474-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-04-26 US disclosed
US-20070093474-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-04-26 US disclosed
US-20070093474-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-04-26 US disclosed
WO-2007030940-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093474-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 KMT2A 4267/4885KLK7 2172/4885FTO 4015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.